DFFN - Diffusion Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Diffusion Pharmaceuticals Inc.

1317 Carlton Avenue
Suite 200
Charlottesville, VA 22902
United States
434-220-0718
http://www.diffusionpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. David G. KalergisCo-Founder, CEO & Chairman522.24kN/A1949
Mr. William Karl HornungChief Financial Officer265.26kN/A1969
Mr. Thomas E. ByrneGen. CounselN/AN/A1957
Dr. David Randolph Jones M.D.Sr. Medical AdvisorN/AN/A1963
Ms. Kelly HoyDirector of Project ManagementN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.

Corporate Governance

Diffusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.